Floatz logo

Cyclophosphamide

Malignant Ovarian Mixed Epithelial Tumor

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the Malignant Ovarian Mixed Epithelial Tumor cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
Carboplatin
National Cancer Institute (NCI)
Phase 3BB
Cediranib
National Cancer Institute (NCI)
Phase 3BB
Olaparib
National Cancer Institute (NCI)
Phase 3BB

View all 41 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →